Background and objectives Patients on hemodialysis frequently experience pain and may be particularly vulnerable to opioid-related complications. However, data evaluating the risks of opioid use in patients on hemodialysis are limited.
Introduction
Pain is among the most commonly reported symptoms in patients on hemodialysis, with a prevalence of up to 81% (1) (2) (3) , and patients on dialysis report more severe pain than the general population on average (4, 5) . Despite evidence of the benefit of opioid analgesics (6) and the availability of opioid prescribing guidelines in ESKD (6) (7) (8) (9) , several studies have suggested that pain is inadequately treated in patients on hemodialysis (10) (11) (12) (13) (14) (15) (16) , and provider concern for adverse drug effects may present a barrier to effective pain management (10, 13) . However, it is plausible that patients on hemodialysis may be especially susceptible to opioid-related complications due to multiple comorbidities, polypharmacy, superimposed uremia, and reduced clearance by the kidney of active drug metabolites, and therefore, caution in their use may be warranted (10, 17) .
In the general population, opioids have been associated with mortality as well as altered mental status, falls, and fractures (18) (19) (20) (21) (22) , which may be mediated by the depressive effects of opioids on the respiratory and central nervous system and their association with decreased bone mineral density (22) (23) (24) (25) (26) . Epidemiologic data regarding the risks of these major opioid complications in patients on hemodialysis are limited to three cohort studies, in which opioid use was associated with all-cause mortality, dialysis discontinuation, hospitalization, and fracture (27, 28) ; also, opioid use was higher among those who experienced a fall, but it was not an independent predictor of fall (29) . However, there is a paucity of literature quantifying the risks of major adverse outcomes associated with opioid use in the United States hemodialysis population and examining their associations according to opioid dose or agent.
Our research objective was to investigate the association between opioid dose and agent with risk of major adverse outcomes (i.e., altered mental status, fall, and fracture) in patients on hemodialysis in the United States. We hypothesized that opioids would be associated with risk of these outcomes in a dose-dependent manner and that the risks associated with the individual opioid agents would align with guideline recommendations for opioid prescribing in patients on hemodialysis (i.e., agents recommended by guidelines would be associated with less harm than agents for which guidelines have recommended cautious use or avoidance) (8, 9) .
Materials and Methods

Study Design and Population
We conducted a retrospective cohort study using data from the US Renal Data System (USRDS) 2013 standard analytic and Medicare payment files, which contain clinical and billing data from 2011, including the Part D prescription drug file. The University of California, San Francisco Committee on Human Research did not consider the study to involve human subjects research.
The study population consisted of prevalent adult Medicare-covered patients receiving chronic maintenance hemodialysis with Part D coverage as of January 2011 ( Figure 1 ). We also required Medicare coverage during 2010 to capture claims data for determining comorbidity status. To maximize accuracy of exposure and outcome ascertainment, we eliminated those with intermittent Part D coverage; dual Veterans Affairs coverage; and no institutional, dialysis, or Part D medication claims in 2011. We also eliminated those with missing body mass index to have complete data for this potential confounding variable.
Patients were also excluded from the cohort if any of the following occurred in January 2011: death, kidney transplant, change in modality away from in-center hemodialysis (e.g., home hemodialysis or peritoneal dialysis), uncertain/recovered function, loss to follow-up, withdrawal from dialysis, or loss of Part D coverage, which precluded our ability to ascertain exposure status as of February 2011.
Exposure Variables
Ascertainment of opioid exposure status was started in January 2011, and the timing of outcome ascertainment was delayed until February 2011 to allow for determination of prior opioid exposure. We used a time-varying definition of opioid exposure, in which a patient was considered to be exposed during periods of opioid medication possession. Our database was created such that there was a record for each person for each day of observation. Using this database structure, we were able to define continuous periods of medication possession as the period starting from the date of service of a prescription plus the number of days supplied (30) . For each prescription, we calculated an average daily dose and converted this into standardized oral morphine equivalents to account for differences in potency among individual opioid agents (Supplemental Table 1 ) (31) . Dosages of opioid and opioid/acetaminophen agents were combined during periods of overlapping possession, and we excluded values exceeding the 95th percentile of oral morphine equivalents. Periods of opioid exposure were then categorized as none (average daily total dose 0 mg), lower dose (0, average daily total dose #60 mg in oral morphine equivalents), or higher dose (average daily total dose .60 mg in oral morphine equivalents) (22) .
The predictor variables were time-updated category of opioid dose use (none, lower, or higher), average daily total opioid dose (expressed as a continuous variable and scaled per 60 mg oral morphine equivalents), and receipt of individual opioid agents (i.e., hydrocodone, oxycodone, tramadol, codeine, hydromorphone, fentanyl, morphine, or methadone; expressed as a continuous variable and scaled per 60 mg oral morphine equivalents). We selected these agents for evaluation, because they were the most commonly used opioid agents in our cohort and represented a spectrum of opioids for which guidelines recommend use (e.g., hydromorphone, fentanyl, and methadone), use with caution (e.g., tramadol, hydrocodone, and oxycodone), or avoidance (e.g., morphine and codeine) (8, 9) .
Outcome Variables
The outcome variables (examined separately) were first episode of altered mental status, fall, and fracture (of the hip, femur, pelvis, leg, foot, arm, hand, or axial skeleton) requiring an emergency room visit or hospitalization during 2011. Using our continuous database structure, we were able to assign specific events dates to the outcomes of interest. We identified emergency room visits and hospitalizations using the revenue, physician/supplier, and institutional claims files. Outcome definitions were determined by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and Current Procedural Terminology codes (Supplemental Table 2 ). We included hospitalizations in which the outcomes of interest were designated as the primary diagnosis in the USRDS according to standard methodology (32) and emergency room visits in which there was a code for the outcomes of interest.
Statistical Analyses
Baseline characteristics of the study cohort are presented as mean6SD or median with 25th and 75th percentiles for continuous variables and percentages for categorical variables. In Table 1 , patients were categorized into the following groups: no opioid use in 2011, lower dose (received only lower doses in 2011), and higher dose (received at least one Results are adjusted for age, sex, race, duration on dialysis, network, body mass index, alcohol dependence, coronary artery disease, cancer, other cardiac disease, dysrhythmia, congestive heart failure, cerebrovascular disease, diabetes, drug dependence, opioid dependence, hypertension, inability to ambulate, inability to transfer, chronic obstructive pulmonary disease, peripheral vascular disease, tobacco dependence, liver disease, dementia, depression, seizures/epilepsy, osteoporosis, osteopenia, skilled nursing facility resident, medication burden, number of hypertensive medications, and concomitant medications. PY, person-year; HR, hazard ratio; 95% CI, 95% confidence interval.
a Periods of lower-dose (0, average daily total dose #60 mg oral morphine equivalents) opioid exposure. b higher dose in 2011). Rates of each of the outcomes were calculated for the overall follow-up time and with followup time stratified by opioid dose category (none, lower, or higher), and they were expressed as the number of events per 100 person-years. For each predictor and outcome pairing, we constructed a Cox model using a time-varying definition of opioid exposure to determine the hazard of each outcome during periods of lower dose compared with no opioid use and periods of higher dose compared with no opioid use. We also determined the hazard per 60-mg increment in average daily total opioid dose and individual opioid agent dose. We also performed an analysis of the associations of the number of concomitant opioid agents (one, two, and three or more versus none), accounting for dose, with outcomes. Exposure was time lagged (i.e., ascertained from the prior day) for fall and fracture to account for the possibility of effect/cause.
We
] as categorical variables), comorbidities (i.e., alcohol dependence, coronary artery disease, cancer, other cardiac disease, dysrhythmia, congestive heart failure, cerebrovascular disease, diabetes, drug dependence, opioid dependence, hypertension, inability to ambulate, inability to transfer, chronic obstructive pulmonary disease, peripheral vascular disease, tobacco dependence, liver disease, dementia, depression, seizures/ epilepsy, osteoporosis, osteopenia, and skilled nursing facility resident as binary variables, indicating the presence or absence of each comorbidity), and number of total unique medications (zero to one, two to three, four to five, six to seven, or eight or more) and antihypertensives (zero, one, two, or three or more) prescribed at baseline as categorical variables. Comorbidities were determined to be present if they appeared on the USRDS Medical Evidence Report or if an appropriate ICD-9-CM diagnosis or procedure code was present on two outpatient claims (on different days) or one inpatient claim during 2010 in the institutional claims or physician/supplier files (Supplemental Table 3 ) (33) (34) (35) (36) . We also controlled for use of concomitant medications that might influence risk of the outcomes (e.g., sedative/hypnotics) as a time-varying covariate.
Patients were censored at the time of death, receipt of a kidney transplant, change in modality away from in-center hemodialysis (e.g., home hemodialysis or peritoneal dialysis), uncertain/recovered function, withdrawal from dialysis, loss to follow-up, discontinuation of Part D coverage, or end of the study period. During every calendar year, there is a Medicare Part D coverage gap (i.e., "donut hole"), which represents a gap in coverage that occurs after the initial coverage limit has been exceeded but before catastrophic coverage applies (37) . The Part D program offers a lowincome subsidy, which provides full or partial coverage during the coverage gap, and lack of a low-income subsidy has been associated with lower medication adherence and persistence in patients with ESKD (38) . Thus, we performed a sensitivity analysis restricting to patients who received the low-income subsidy and would be incentivized to obtain all of their prescriptions with Medicare Part D (39) . We also performed a sensitivity analysis using a new user approach (28) , in which we excluded patients with an opioid prescription from January 1, 2011 to March 31, 2011 and evaluated associations between opioid use and outcomes during the remainder of 2011. We performed subgroup analyses by age, sex, race, and dialysis duration. Testing for statistical significance was two tailed, and P,0.05 was considered significant. Analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC).
Results
Demographics, Opioid Use, and Incidence of Outcomes
Our cohort consisted of 140,899 Medicare-covered adults receiving in-center hemodialysis with Part D coverage in 2011 (Figure 1) . The median age of the cohort was 61 years old (25th-75th percentiles, 51-72 years old), 52% were men, and 50% were white. Opioid use was associated with younger age, women, black race, higher body mass index, and higher prevalence of comorbidities (Table 1) .
Opioids were frequently prescribed, with 90,124 (64%) patients receiving opioid analgesics in 2011 and 32,730 (23%) receiving at least one high-dose prescription. The prevalence of use of the individual agents of interest was as follows: hydrocodone (43%), oxycodone (22%), tramadol (15%), codeine (7%), hydromorphone (3%), fentanyl (3%), morphine (2%), and methadone (1%).
Seventeen percent of patients (23, 715) had an episode of altered mental status, fall, or fracture in 2011, and 11% (15,658 events), 5% (7,646 events), and 3% (4,151 events) had an episode of altered mental status, fall, and fracture in 2011, respectively. The overall rates of first episode of altered mental status, fall, and fracture in the cohort were 15, 7, and 4 per 100 person-years, respectively. The rates of these adverse outcomes were highest during periods of possession of higher doses of opioids followed by periods of possession of lower doses and then, periods of nonuse: altered mental status (29, 20 , and 13 per 100 person-years), fall (12, 10, and 6 per 100 person-years), and fracture (6, 5, and 3 per 100 person-years).
Associations between Total Opioid Dose and Outcomes
Compared with no opioid use, lower-and higher-dose opioid use was associated with higher hazard of altered mental status (adjusted hazard ratio [HR], 1.28 for lower dose; 95% confidence interval [95% CI], 1.23 to 1.34; P,0.001 and HR, 1.67 for higher dose; 95% CI, 1.56 to 1.78; P,0.001), fall (HR, 1.28 for lower dose; 95% CI, 1.21 to 1.36; P,0.001 and HR, 1.45 for higher dose; 95% CI, 1.31 to 1.61; P,0.001), and fracture (HR, 1.44 for lower dose; 95% CI, 1.33 to 1.56; P,0.001 and HR, 1.65 for higher dose; 95% CI, 1.44 to 1.89; P,0.001) ( Table 2) . Each 60-mg increment in dose (in standardized oral morphine equivalents) of any opioid was associated with a 29% higher hazard of altered mental status (95% CI, 26% to 33%; P,0.001), 4% higher hazard of fall (3%-5%; P,0.001), and 4% higher hazard of fracture (4%-5%; P,0.001).
Associations between Individual Opioid Agents and Outcomes
All individual agents were associated with a significantly higher hazard of altered mental status ranging from 14% to 365% per 60 mg (Table 2) . Hydromorphone, hydrocodone, oxycodone, and tramadol were associated with a significantly higher risk of fall (2%-42% higher hazard per 60 mg), and hydromorphone, hydrocodone, oxycodone, tramadol, and codeine were associated with a significantly higher risk of fracture (3%-294% higher hazard per 60 mg). For altered mental status, fall, and fracture, the highest hazards were associated with codeine, a medication for which guidelines recommend avoidance.
Additional Analyses
The magnitude of the associations was similar in the sensitivity analysis restricted to patients with the lowincome subsidy (Supplemental Table 4 ). In the new user analysis, the magnitude of the associations was stronger (Supplemental Table 5 ). The associations were similar among users of one, two, and three or more concomitant opioid agents accounting for opioid dose (Supplemental Table 6 ). The relative risk of altered mental status associated with opioid use is greater for nonblacks than blacks (Supplemental Table 7 ).
Discussion
In our study of patients on hemodialysis with Medicare Part D coverage, we observed that opioid use was common and associated with risk for altered mental status, fall, and fracture in a dose-dependent manner, and the risk was present even when patients were not prescribed high doses. The relative risk of altered mental status associated with opioid use was higher among nonblacks than blacks. The magnitude of the associations was larger in the new user analysis, consistent with prior literature in which the risks of opioids were most pronounced in the time period immediately after onset of use (22, 40) . We also observed that all agents were associated with altered mental status, and several agents were associated with fall and fracture. Notably, even agents recommended for use in this population were associated with risk for adverse outcomes.
Our data are consistent with the limited available epidemiologic evidence that has suggested that patients on hemodialysis receiving opioids are at higher risk of major complications. In a study of approximately 150,000 United States patients on hemodialysis in the USRDS, opioid use was associated with all-cause mortality, dialysis discontinuation, and hospitalization (28) . Our analysis, in which we focused on outcomes that could be temporally related to opioid use, is complementary to this study. Among patients on hemodialysis, opioid use has been associated with altered mental status in patient reports (41, 42) , and opioid medications were associated with a higher adjusted risk of hip and other fractures in an international study of 12,782 patients on hemodialysis (27) . Our study observed that opioid use was associated with risk for fall in contrast to a study of 308 Belgian patients on hemodialysis, in which opioid use was higher among those who experienced a fall but was not independently associated with fall (29) . The discrepant findings may be due to differences in study population, sample size, and methodology (e.g., exposure and outcome ascertainment or analytic approach).
Despite the high prevalence of pain among patients on hemodialysis (1-3) , studies of the efficacy and safety of opioid medications in this population are scarce, and clinical practice guidelines for prescribing opioids in the setting of dialysis are on the basis of limited pharmacokinetic and anecdotal data (4, 43) . Nonetheless, recommendations consistently advise avoidance of morphine and codeine, which are converted to active metabolites that accumulate in the setting of kidney failure, leading to adverse effects, such as central nervous system and respiratory depression (8, 9, 43, 44) . In particular, both are metabolized to morphine-6-glucuronide, which is more potent than morphine itself, equilibrates slowly across the blood-brain barrier, and may result in prolonged sedation (4, 43, 45) . Guidelines recommend that hydrocodone, oxycodone, and tramadol be used with caution given that their pharmacokinetic profile has not been well established in the setting of kidney failure (4, 8, 9, 46, 47) . Fentanyl and methadone are thought to be relatively safe, because they are converted to inactive metabolites, but they require management and careful monitoring by experienced practitioners (44, 48) . Hydromorphone is thought to be better tolerated than morphine among those with kidney impairment (49) , and although its active metabolite, hydromorphone-3-glucuronide, is excreted by the kidneys, it is rapidly dialyzed, which may make it a safe choice for patients on hemodialysis (4, 43) .
In our study, prescription of morphine was uncommon, suggesting that providers are following recommendations to avoid its use. However, despite the guidance to avoid codeine, its use was more common than recommended agents. Our results support the recommendation to avoid morphine and codeine, because receipt of these agents was associated with adverse outcomes. Hydrocodone, oxycodone, and tramadol were the most commonly used agents, and our results also support the recommendation to use these agents with caution, because they were each associated with all of the adverse outcomes. However, despite guidance recommending hydromorphone, fentanyl, and methadone, use of these agents was relatively uncommon, and they were also associated with adverse outcomes.
Our study has several limitations. Given that our study was observational, we cannot exclude the possibility of confounding by indication. However, we controlled for many important covariates, including demographics, comorbidities, medication burden, and potentially confounding concomitant medications (e.g., sedatives/hypnotics) to mitigate this concern. Opioid exposure was determined on the basis of Medicare Part D claims data, and previous work in the USRDS has shown the accuracy of the Medicare Part D claims to ascertain medication prescriptions (50) . However, we do not know with certainty whether patients took their prescribed medications and the exact time period over which medications were consumed. Additionally, we were unable to distinguish scheduled versus as-needed dosing. Ascertainment of the outcomes was limited by the use of ICD-9-CM codes. However, it is unlikely that misclassification of opioid exposure would differ by outcome or that misclassification of the outcome would differ by opioid exposure. To the extent that nondifferential misclassification occurred, it would be expected to bias the results to the null, and therefore, our findings may represent a conservative estimate. Although we found that opioid prescription was common, we lacked information about the clinical context for the prescriptions (e.g., specific indications and level of pain), and therefore, we are unable to comment on the adequacy of pain management in our cohort. Finally, we are unable to determine whether the different associations by race are due to biologic factors, residual confounding, or chance, and these associations warrant further investigation. Strengths of our study are the large sample size and detailed medication data contained in the Medicare Part D claims, which enabled investigation of associations according to opioid dose and specific agents.
Pain is a highly prevalent symptom in patients on hemodialysis (1) (2) (3) , and this population may be particularly vulnerable to complications related to opioid use. We observed that opioids were associated with a significantly higher risk of altered mental status, fall, and fracture in patients receiving hemodialysis, even at lower dosing and for agents recommended by guidelines. Thus, opioid use in patients on hemodialysis may not be as safe as guidelines suggest, and the benefit-to-risk ratio of their use in this population should be carefully considered. Future research and strategies to predict and mitigate the risks of opioid use in patients on hemodialysis are warranted. This study was presented as an oral abstract at the annual meeting of the American Society of Nephrology on November 4, 2017 in New Orleans, Louisiana.
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